PubMed 23886683

Referenced in: none

Automatically associated channels: Cav1.2 , Kv11.1 , Nav1.5 , TRP , TRPA , TRPA1 , TRPC , TRPC3 , TRPC6 , TRPV , TRPV1 , TRPV4

Title: The discovery of potent blockers of the canonical transient receptor channels, TRPC3 and TRPC6, based on an anilino-thiazole pharmacophore.

Authors: David G Washburn, Dennis A Holt, Jason Dodson, Jeff J McAtee, Lamont R Terrell, Linda Barton, Sharada Manns, Anna Waszkiewicz, Christina Pritchard, Dan J Gillie, Dwight M Morrow, Elizabeth A Davenport, Irina M Lozinskaya, Jeffrey Guss, Jonathan B Basilla, Lorena Kallal Negron, Michael Klein, Robert N Willette, Rusty E Fries, Timothy C Jensen, Xiaoping Xu, Christine G Schnackenberg, Joseph P Marino

Journal, date & volume: Bioorg. Med. Chem. Lett., 2013 Sep 1 , 23, 4979-84

PubMed link: http://www.ncbi.nlm.nih.gov/pubmed/23886683

Abstract
Lead optimization of piperidine amide HTS hits, based on an anilino-thiazole core, led to the identification of analogs which displayed low nanomolar blocking activity at the canonical transient receptor channels 3 and 6 (TRPC3 & 6) based on FLIPR (carbachol stimulated) and electrophysiology (OAG stimulated) assays. In addition, the anilino-thiazole amides displayed good selectivity over other TRP channels (TRPA1, TRPV1, and TRPV4), as well as against cardiac ion channels (CaV1.2, hERG, and NaV1.5). The high oxidation potential of the aliphatic piperidine and aniline groups, as well as the lability of the thiazole amide group contributed to the high clearance observed for this class of compounds. Conversion of an isoquinoline amide to a naphthyridine amide markedly reduced clearance for the bicyclic piperidines, and improved oral bioavailability for this compound series, however TRPC3 and TRPC6 blocking activity was reduced substantially. Although the most potent anilino-thiazole amides ultimately lacked oral exposure in rodents and were not suitable for chronic dosing, analogs such as 14-19, 22, and 23 are potentially valuable in vitro tool compounds for investigating the role of TRPC3 and TRPC6 in cardiovascular disease.